KEYNOTE-100: Final Results From Phase II Study on Pembrolizumab Monotherapy for Advanced Recurrent Ovarian Cancer

May 29-31, 2020; Online at
Pembrolizumab monotherapy resulted in ORR of 8.5% with median DoR of 10.2 mos and median OS of 18.7 mos in patients with advanced recurrent ovarian cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 321 KB
Released: June 8, 2020


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Merck Sharp & Dohme Corp
Novartis Pharmaceuticals Corporation

Related Content

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

From ASCO 2020, niraparib plus bevacizumab prolonged PFS and time to subsequent therapies over niraparib alone in recurrent ovarian cancer as reported by Clinical Care Options (CCO)

Released: June 8, 2020

DESKTOP III results from ASCO 2020 show substantial survival benefit with complete resection in select patients with ovarian cancer as reported by Clinical Care Options (CCO)

Released: June 3, 2020

Analyses of optimal niraparib dosing in ovarian cancer and in patients with moderate hepatic impairment from ASCO 2020, as reported by Clinical Care Options (CCO)

Released: June 1, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?